Zydus receives tentative approval from the USFDA for Macitentan Tablets
2020-04-15 · Zydus Lifesciences Limited · original zyduslife.com ↗
Zydus receives tentative approval from the USFDA for Macitentan Tablets Ahmedabad, April 15, 2020 Zydus Worldwide DMCC, a wholly owned subsidiary of Cadila Healthcare Limited, has received tentative approval from the USFDA to market Macitentan Tablets (US RLD: Opsumit® Tablets), 10 mg. The medication is indicated for the treatment of pulmonary arterial hypertension. The drug will be manufactured at CMO Umedica Laboratories Pvt Ltd., Vapi, Gujarat. The group now has 287 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***
The release as fetched from its publisher. zyduslife.com ↗